Dr. Hong Yu 于洪
Chief Physician
Department of Radiation Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy for lung, esophageal, rectal, breast, and nasopharyngeal cancers, malignant lymphoma, and radiation protection of normal tissues.
Dr. Yu is Chief Physician and Director of the Radiotherapy Department at Liaoning Cancer Hospital & Institute. A master’s supervisor, Dr. Yu leads provincial and municipal research projects and has published multiple papers. Research focuses on radiotherapy for lung, esophageal, nasopharyngeal, breast, and rectal cancers, and radiation protection.
Professional roles
- Member, Radiation Oncology Branch, Chinese Medical Association
- Member, Radiation Oncology Professional Committee, China Anti-Cancer Association
- Member, Nasopharyngeal Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Radiation Oncology Branch, Liaoning Medical Association
Name order: in Chinese the family name comes first (Yu Hong). Papers usually list the name as Hong Yu or Yu H.
Selected publications
14 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Dis Markers, 2022 (senior author): Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis. PubMed 35320950
- Front Oncol, 2022 (senior author): Benefits of Prophylactic Cranial Irradiation in the MRI Era for Patients With Limited Stage Small Cell Lung Cancer. PubMed 35296010
- Front Oncol, 2021 (senior author): Optimizing Whole Brain Radiotherapy Treatment and Dose for Patients With Brain Metastases From Small Cell Lung Cancer. PubMed 34760692
- Biomark Med, 2021 (senior author): Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases. PubMed 34397267
- Ann Palliat Med, 2021 (senior author): Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report. PubMed 34488412
- Biomed Res Int, 2021 (senior author): Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer. PubMed 33987445
- Biomark Med, 2020 (senior author): Initial neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with inoperable locally advanced non-small-cell lung cancer. PubMed 32808809
- J Cancer Res Clin Oncol, 2020 (senior author): Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. PubMed 31813004
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion